ENDMC
MCID: END057
MIFTS: 69

Endometrial Cancer (ENDMC)

Categories: Cancer diseases, Genetic diseases, Reproductive diseases

Aliases & Classifications for Endometrial Cancer

MalaCards integrated aliases for Endometrial Cancer:

Name: Endometrial Cancer 58 12 76 38 13 56 15
Endometrial Carcinoma 12 30 13 56 6 15 17 74
Endometrial Neoplasm 12 30 6 17
Malignant Neoplasm of Endometrium 12 74
Carcinoma, Endometrioid 45 74
Endometrioid Carcinoma 12 17
Endometrial Neoplasms 45 74
Endometrioid Carcinoma of Female Reproductive System 12
Primary Malignant Neoplasm of Endometrium 12
Endometrial Cancer, Susceptibility to 58
Endometrial Carcinoma, Somatic 58
Malignant Endometrial Neoplasm 12
Endometrial Cancer, Familial 58
Carcinoma of the Endometrium 12
Neoplasm of Endometrium 12
Carcinoma Endometrioid 56
Uterine Corpus Cancer 74
Tumor of Endometrium 12
Cancer, Endometrial 41
Endometrial Ca 12
Endmc 76

Classifications:



External Ids:

Disease Ontology 12 DOID:1380 DOID:2871
OMIM 58 608089
KEGG 38 H00026
SNOMED-CT 69 30289006 93781006
ICD10 34 C54.1
MedGen 43 C0476089
SNOMED-CT via HPO 70 254878006

Summaries for Endometrial Cancer

UniProtKB/Swiss-Prot : 76 Endometrial cancer: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.

MalaCards based summary : Endometrial Cancer, also known as endometrial carcinoma, is related to lynch syndrome and adenocarcinoma. An important gene associated with Endometrial Cancer is MSH6 (MutS Homolog 6), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs Peppermint and Megestrol acetate have been mentioned in the context of this disorder. Affiliated tissues include lymph node, breast and uterus, and related phenotypes are endometrial carcinoma and Decreased viability

Disease Ontology : 12 A endometrial cancer that is located in the tissue lining the uterus.

Wikipedia : 77 Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). It... more...

Description from OMIM: 608089

Related Diseases for Endometrial Cancer

Diseases related to Endometrial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 327)
# Related Disease Score Top Affiliating Genes
1 lynch syndrome 33.4 CTNNB1 KRAS MLH3 MSH3 MSH6 MUTYH
2 adenocarcinoma 31.4 CDH1 CTNNB1 FGFR2 KRAS PTEN
3 breast cancer 31.2 CASC2 CDH1 CTNNB1 FGFR2 GAS5 HOTAIR
4 carcinosarcoma 31.2 CTNNB1 KRAS PTEN
5 colorectal cancer 31.0 CASC2 CDH1 CTNNB1 GAS5 HOTAIR KRAS
6 ovarian cancer 31.0 CDH1 CTNNB1 GAS5 HOTAIR KRAS LINC-ROR
7 adenoid cystic carcinoma 31.0 CDH1 CTNNB1 KRAS PTEN
8 endometrial adenocarcinoma 30.9 CTNNB1 FGFR2 KRAS PTEN
9 familial adenomatous polyposis 30.9 CDH1 CTNNB1 KRAS MSH3 MSH6 MUTYH
10 uterine carcinosarcoma 30.9 CDH1 CTNNB1 FGFR2 PTEN
11 mismatch repair cancer syndrome 30.8 CTNNB1 MSH6 PTEN
12 cervical cancer 30.8 CDH1 CTNNB1 GAS5 HOTAIR PTEN UCA1
13 uterine anomalies 30.7 CDH1 CTNNB1 MSH6 PTEN
14 squamous cell carcinoma 30.7 CDH1 CTNNB1 FGFR2 HOTAIR PTEN UCA1
15 gallbladder cancer 30.6 CDH1 HOTAIR KRAS LINC-ROR UCA1
16 thyroid cancer 30.4 CASC2 CDH1 CTNNB1 GAS5 HOTAIR KRAS
17 myeloma, multiple 30.3 GAS5 HOTAIR KRAS UCA1
18 pancreatic cancer 30.3 CASC2 CDH1 CTNNB1 GAS5 HOTAIR KRAS
19 lung cancer 30.2 CASC2 CDH1 FGFR2 GAS5 HOTAIR KRAS
20 melanoma 30.1 GAS5 HOTAIR LINC-ROR MIR200C PTEN UCA1
21 renal cell carcinoma, nonpapillary 30.1 CASC2 CDH1 GAS5 HOTAIR LINC-ROR MIR200C
22 female reproductive endometrioid cancer 30.1 CTNNB1 PTEN
23 uterine corpus endometrial carcinoma 12.3
24 ovarian endometrial cancer 12.1
25 fallopian tube endometrioid adenocarcinoma 11.5
26 polycystic ovary syndrome 11.4
27 high-grade neuroendocrine carcinoma of the corpus uteri 11.3
28 cervical endometrioid adenocarcinoma 11.1
29 cowden syndrome 1 11.1
30 endometrial transitional cell carcinoma 11.1
31 endometrial squamous cell carcinoma 11.1
32 endometrial adenosquamous carcinoma 11.1
33 endometrium carcinoma in situ 11.1
34 lynch syndrome i 11.0
35 precocious puberty, central, 1 11.0
36 polycystic ovary syndrome 1 11.0
37 colorectal cancer, hereditary nonpolyposis, type 5 11.0
38 precocious puberty, central, 2 11.0
39 female reproductive system disease 10.7 CDH1 CTNNB1 MSH6 PTEN
40 colonic disease 10.7 CDH1 CTNNB1 KRAS MSH6
41 colorectal adenocarcinoma 10.7 CDH1 CTNNB1 KRAS MSH6
42 respiratory system cancer 10.7 CDH1 CTNNB1 KRAS PTEN
43 reproductive system disease 10.7 CDH1 CTNNB1 PTEN
44 endocrine gland cancer 10.7 CDH1 CTNNB1 KRAS PTEN
45 intrahepatic cholangiocarcinoma 10.7 CDH1 CTNNB1 FGFR2 KRAS
46 colon adenocarcinoma 10.7 CDH1 CTNNB1 KRAS MSH6
47 intestinal disease 10.7 CDH1 CTNNB1 KRAS MSH6 MUTYH
48 lung squamous cell carcinoma 10.7 CDH1 FGFR2 KRAS PTEN
49 gastric adenocarcinoma 10.7 CDH1 CTNNB1 FGFR2 HOTAIR KRAS PTEN
50 anaplastic thyroid cancer 10.7 CDH1 CTNNB1 PTEN

Graphical network of the top 20 diseases related to Endometrial Cancer:



Diseases related to Endometrial Cancer

Symptoms & Phenotypes for Endometrial Cancer

Human phenotypes related to Endometrial Cancer:

33
# Description HPO Frequency HPO Source Accession
1 endometrial carcinoma 33 HP:0012114

Clinical features from OMIM:

608089

GenomeRNAi Phenotypes related to Endometrial Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.55 KRAS
2 Decreased viability GR00106-A-0 9.55 KRAS
3 Decreased viability GR00221-A-1 9.55 CDH1 KRAS
4 Decreased viability GR00221-A-2 9.55 KRAS
5 Decreased viability GR00301-A 9.55 CDH1 FGFR2 KRAS MLH3
6 Decreased viability GR00342-S-1 9.55 FGFR2
7 Decreased viability GR00342-S-2 9.55 FGFR2
8 Decreased viability GR00342-S-3 9.55 FGFR2
9 Decreased viability GR00381-A-1 9.55 KRAS
10 Decreased viability GR00402-S-2 9.55 CDH1 FGFR2 KRAS MLH3

MGI Mouse Phenotypes related to Endometrial Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 CDH1 CTNNB1 FGFR2 KRAS MSH3 MSH6

Drugs & Therapeutics for Endometrial Cancer

Drugs for Endometrial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peppermint Approved Phase 4
2
Megestrol acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 595-33-5 11683
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
4
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 71-58-9
5
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2 28014-46-2
6
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
7 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1
9 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
10 Appetite Stimulants Phase 4,Phase 3,Phase 2,Phase 1
11 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13
Megestrol Phase 4,Phase 3,Phase 2,Phase 1 3562-63-8 19090 3080587
14 Contraceptive Agents, Male Phase 4,Phase 2,Phase 3
15 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2
17 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2
18
Medroxyprogesterone Phase 4,Phase 2,Phase 3,Not Applicable 520-85-4 10631
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Fluorodeoxyglucose F18 Phase 4,Phase 1,Phase 2,Not Applicable
22 taxane Phase 4,Phase 1,Not Applicable
23 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24
Sargramostim Approved, Investigational Phase 3,Phase 1,Phase 2 123774-72-1, 83869-56-1
25
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
26
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
27
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
28
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 38904 10339178 498142
29
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33069-62-4 36314
30
Sodium Citrate Approved, Investigational Phase 3,Phase 2 68-04-2
31
Levonorgestrel Approved, Investigational Phase 3,Phase 2,Not Applicable 17489-40-6, 797-63-7 13109
32
Methylene blue Approved, Investigational Phase 3,Not Applicable 61-73-4
33
Progesterone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 57-83-0 5994
34
Letrozole Approved, Investigational Phase 3,Phase 2,Not Applicable 112809-51-5 3902
35
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
36
Atezolizumab Approved, Investigational Phase 3,Phase 2,Phase 1 1380723-44-3
37
Tamoxifen Approved Phase 3,Phase 2,Phase 1 10540-29-1 2733526
38
Epirubicin Approved Phase 3 56420-45-2 41867
39
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
40
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
41
Pembrolizumab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 1374853-91-4
42
Lenvatinib Approved, Investigational Phase 3,Phase 2,Phase 1 417716-92-8
43
Ifosfamide Approved Phase 3 3778-73-2 3690
44
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
45
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
46
Gemcitabine Approved Phase 2, Phase 3,Phase 1 95058-81-4 60750
47
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 1 123948-87-8, 119413-54-6 60700
48
Niraparib Approved, Investigational Phase 2, Phase 3,Phase 1 1038915-60-4 24958200
49
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
50
Exemestane Approved, Investigational Phase 3,Phase 2,Not Applicable 107868-30-4 60198

Interventional clinical trials:

(show top 50) (show all 751)
# Name Status NCT ID Phase Drugs
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Unknown status NCT00719017 Phase 4
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Recruiting NCT03349463 Phase 4 Fluciclovine F18
4 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. Recruiting NCT03423082 Phase 4 18F fluciclovine
5 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
6 Application of Tachosil During Lymphadenectomy Completed NCT03752606 Phase 4
7 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4 arzoxifene
8 Pharmacokinetics and Safety of Transdermal Megestrol Acetate Withdrawn NCT00163072 Phase 4 transdermal Megace
9 Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia Completed NCT02872818 Phase 4 17β estradiol hemihydrate;Metformin;medroxyprogesterone acetate
10 Role of Uterine Manipulator in Hysterectomy - Ro.Man.HY Unknown status NCT02762214 Phase 3
11 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Unknown status NCT00063999 Phase 3 Carboplatin;Cisplatin;Doxorubicin Hydrochloride;Paclitaxel
12 Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause Unknown status NCT00925639 Phase 3 Isoflavone;Placebo
13 Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet. Unknown status NCT01414517 Phase 3
14 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
15 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
16 Atezolizumab Trial in Endometrial Cancer - AtTEnd Recruiting NCT03603184 Phase 3 Atezolizumab;Placebos;Paclitaxel;Carboplatin
17 VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for Endometrial Cancer Patients. Not yet recruiting NCT03324958 Phase 3
18 Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer. Recruiting NCT03555422 Phase 3 Selinexor;Placebo
19 Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer Terminated NCT00016341 Phase 3 cisplatin;doxorubicin hydrochloride;megestrol acetate;paclitaxel;tamoxifen citrate
20 External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer Completed NCT00376844 Phase 3
21 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
22 Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome Terminated NCT00566644 Phase 3
23 A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer Terminated NCT00883116 Phase 3 Ixabepilone;Doxorubicin;Paclitaxel
24 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
25 Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Completed NCT00003691 Phase 3 cisplatin;doxorubicin hydrochloride;paclitaxel
26 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
27 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
28 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
29 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed NCT01767155 Phase 3 AEZS-108 / zoptarelin doxorubicin;doxorubicin
30 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
31 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
32 Laparoscopic Approach to Cancer of the Endometrium Completed NCT00096408 Phase 3
33 Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer Terminated NCT00002976 Phase 3 conjugated estrogens
34 Regional Anesthesia and Endometrial Cancer Recurrence Withdrawn NCT00531349 Phase 3 Sevoflurane
35 Vaginal Cuff Brachytherapy Fractionation Study Recruiting NCT03785288 Phase 3
36 An Endometrial Cancer Chemoprevention Study of Metformin Active, not recruiting NCT01697566 Phase 3 Metformin
37 Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer Recruiting NCT03241914 Phase 2, Phase 3 Megestrol Acetate
38 Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer Completed NCT02564276 Phase 3
39 Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Recruiting NCT03517449 Phase 3 Pembrolizumab;Lenvatinib;Paclitaxel;Doxorubicin
40 Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. Recruiting NCT02598219 Phase 3 Pre-operative SN mapping with radionucleide;Intra-operative SN mapping with patent V blue dye;Intra-operative SN mapping with indocyanin green
41 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
42 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
43 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
44 Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC Recruiting NCT03463252 Phase 2, Phase 3 Progesterone;GnRH agonist
45 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
46 Tachosil for the Prevention of Symptomatic Lymph Cysts Completed NCT01470677 Phase 3 Tachosil fibrin patch
47 The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma Recruiting NCT01820858 Phase 3 Paclitaxel;Paraplatin (Carboplatin Injection)
48 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) Not yet recruiting NCT03884101 Phase 3 Lenvatinib;Paclitaxel;Carboplatin
49 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
50 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3

Search NIH Clinical Center for Endometrial Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: endometrial neoplasms

Genetic Tests for Endometrial Cancer

Genetic tests related to Endometrial Cancer:

# Genetic test Affiliating Genes
1 Endometrial Carcinoma 30 CDH1 MLH3 MSH3 MSH6
2 Endometrial Neoplasm 30

Anatomical Context for Endometrial Cancer

MalaCards organs/tissues related to Endometrial Cancer:

42
Lymph Node, Breast, Uterus, Testes, Endothelial, Ovary, Colon

The Foundational Model of Anatomy Ontology organs/tissues related to Endometrial Cancer:

20
The Tissue Lining The Uterus

Publications for Endometrial Cancer

Articles related to Endometrial Cancer:

(show top 50) (show all 7547)
# Title Authors Year
1
Impact of gene-specific germline pathogenic variants on presentation of endometrial cancer in Lynch syndrome. ( 30772826 )
2019
2
A proposal for updating the staging of endometrial cancer. ( 30776091 )
2019
3
Macrophage ERα promoted invasion of endometrial cancer cell by mTOR/KIF5B -mediated epithelial to mesenchymal transition. ( 30779215 )
2019
4
A four-miRNA signature as a novel biomarker for predicting survival in endometrial cancer. ( 30779946 )
2019
5
Exploring lncRNA-Mediated Regulatory Networks in Endometrial Cancer Cells and the Tumor Microenvironment: Advances and Challenges. ( 30781521 )
2019
6
Laparoscopic versus Laparotomy: Staging Surgery for Endometrial Cancer - Malaysia's Early Experience. ( 30783585 )
2019
7
Impact and cost of preoperative computed tomography imaging on the management of patients diagnosed with high-grade endometrial cancer. ( 30784043 )
2019
8
High expression of MUC20 drives tumorigenesis and predicts poor survival in endometrial cancer. ( 30784116 )
2019
9
Mutation Frequencies in Endometrial Cancer Patients of Different Ethnicities and Tumor Grades: An Analytical Study. ( 30787852 )
2019
10
Metabolic syndrome and risk of endometrial cancer in postmenopausal women: a prospective study. ( 30788634 )
2019
11
Conservative treatment for well-differentiated endometrial cancer: when and why it should be considered in young women. ( 30792809 )
2019
12
Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. ( 30793281 )
2019
13
RISUG® based improved intrauterine contraceptive device (IIUCD) could impart protective effects against development of endometrial cancer. ( 30798920 )
2019
14
Neoadjuvant Chemoradiotherapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix. ( 30802615 )
2019
15
Expression of NRP-1 and NRP-2 in Endometrial Cancer. ( 30806307 )
2019
16
New insights into early recovery after robotic surgery for endometrial cancer. ( 30808516 )
2019
17
Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. ( 30808517 )
2019
18
Antidiabetic Medications and the Risk of Endometrial Cancer in Patients. ( 30808843 )
2019
19
Harnessing Minimally Invasive Surgery to Improve Outcomes in Endometrial Cancer Surgery-The Robots Are Coming. ( 30810712 )
2019
20
Nationwide Introduction of Minimally Invasive Robotic Surgery for Early-Stage Endometrial Cancer and Its Association With Severe Complications. ( 30810740 )
2019
21
NADPH oxidase 4 expression in the normal endometrium and in endometrial cancer. ( 30813866 )
2019
22
Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line. ( 30813939 )
2019
23
Colony‑stimulating factor 1 receptor inhibition blocks macrophage infiltration and endometrial cancer cell proliferation. ( 30816518 )
2019
24
Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia. ( 30826750 )
2019
25
Correlation between pre-operative and final histological diagnosis on endometrial cancer. ( 30826751 )
2019
26
GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. ( 30827726 )
2019
27
Genetics of IL6 polymorphisms: Case-control study of the risk of endometrial cancer. ( 30828987 )
2019
28
The role of lipocalin-2 serum levels in the diagnostics of endometrial cancer. ( 30829613 )
2019
29
SPOCK2 Affects the Biological Behavior of Endometrial Cancer Cells by Regulation of MT1-MMP and MMP2. ( 30832559 )
2019
30
Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells. ( 30833134 )
2019
31
Risk of empty lymph node packets in sentinel lymph node mapping for endometrial cancer using indocyanine green. ( 30833439 )
2019
32
Impact of Metastatic Lymph Node to Total Lymph Node Ratio on Survival of Endometrial Cancer Patients. ( 30836353 )
2019
33
Autocrine motility factor promotes endometrial cancer progression by targeting GPER-1. ( 30836961 )
2019
34
An Efficacious Endometrial Sampler for Screening Endometrial Cancer. ( 30838173 )
2019
35
MiR-218 suppresses metastasis and invasion of endometrial cancer via negatively regulating ADD2. ( 30840261 )
2019
36
Metformin inhibits proliferation and migration of endometrial cancer cells through regulating PI3K/AKT/MDM2 pathway. ( 30840303 )
2019
37
Lymphadenectomy in elderly patients with high-intermediate-risk, high-risk or advanced endometrial cancer: Time to move from personalized cancer medicine to personalized patient medicine! ( 30846299 )
2019
38
Differential gene expression induced by Verteporfin in endometrial cancer cells. ( 30846786 )
2019
39
Immune response characterization of endometrial cancer. ( 30847026 )
2019
40
Sociodemographic disparities in stage-specific incidences of endometrial cancer: a registry-based study in West Sweden, 1995-2016. ( 30849264 )
2019
41
Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression. ( 30849641 )
2019
42
Genome-wide DNA methylation profile of early-onset endometrial cancer: Its correlation with genetic aberrations and comparison with late-onset endometrial cancer. ( 30850842 )
2019
43
The prognostic significance of positive peritoneal cytology in endometrial cancer and its correlations with L1-CAM biomarker. ( 30851892 )
2019
44
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. ( 30853360 )
2019
45
TRAF4 promotes endometrial cancer cell growth and migration by activation of PI3K/AKT/Oct4 signaling. ( 30853613 )
2019
46
Learning curve and surgical outcomes for laparoscopic surgery, including pelvic lymphadenectomy, for early stage endometrial cancer. ( 30855684 )
2019
47
A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables. ( 30857319 )
2019
48
Combined silencing of VEGF-A and angiopoietin-2, a more effective way to inhibit the Ishikawa endometrial cancer cell line. ( 30863089 )
2019
49
A Micro-Costing Study of Screening for Lynch Syndrome-Associated Pathogenic Variants in an Unselected Endometrial Cancer Population: Cheap as NGS Chips? ( 30863719 )
2019
50
Proteomic analysis of stromal and epithelial cell communications in human endometrial cancer using a unique 3D co-culture model. ( 30865368 )
2019

Variations for Endometrial Cancer

UniProtKB/Swiss-Prot genetic disease variations for Endometrial Cancer:

76
# Symbol AA change Variation ID SNP ID
1 PTEN p.His123Tyr VAR_026260 rs786204931

ClinVar genetic disease variations for Endometrial Cancer:

6 (show top 50) (show all 91)
# Gene Variation Type Significance SNP ID Assembly Location
1 MSH6 NM_000179.2(MSH6): c.10C> T (p.Gln4Ter) single nucleotide variant Pathogenic/Likely pathogenic rs786201042 GRCh38 Chromosome 2, 47783243: 47783243
2 MSH6 NM_000179.2(MSH6): c.10C> T (p.Gln4Ter) single nucleotide variant Pathogenic/Likely pathogenic rs786201042 GRCh37 Chromosome 2, 48010382: 48010382
3 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh37 Chromosome 1, 45798475: 45798475
4 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh38 Chromosome 1, 45332803: 45332803
5 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic/Likely pathogenic rs36053993 GRCh37 Chromosome 1, 45797228: 45797228
6 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic/Likely pathogenic rs36053993 GRCh38 Chromosome 1, 45331556: 45331556
7 MLH3 NM_001040108.1(MLH3): c.2221G> T (p.Val741Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs28756990 GRCh37 Chromosome 14, 75514138: 75514138
8 MLH3 NM_001040108.1(MLH3): c.2221G> T (p.Val741Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs28756990 GRCh38 Chromosome 14, 75047435: 75047435
9 MLH3 NM_001040108.1(MLH3): c.885delG (p.His296Thrfs) deletion Pathogenic GRCh38 Chromosome 14, 75048771: 75048771
10 MLH3 NM_001040108.1(MLH3): c.885delG (p.His296Thrfs) deletion Pathogenic GRCh37 Chromosome 14, 75515474: 75515474
11 PTEN NM_000314.6(PTEN): c.253+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs587776667 GRCh37 Chromosome 10, 89690847: 89690847
12 PTEN NM_000314.6(PTEN): c.253+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs587776667 GRCh38 Chromosome 10, 87931090: 87931090
13 MSH3 NM_002439.4(MSH3): c.1148delA (p.Lys383Argfs) deletion Pathogenic rs587776701 GRCh38 Chromosome 5, 80675103: 80675103
14 MSH3 NM_002439.4(MSH3): c.1148delA (p.Lys383Argfs) deletion Pathogenic rs587776701 GRCh37 Chromosome 5, 79970922: 79970922
15 CDH1 NM_004360.4(CDH1): c.2131C> G (p.Leu711Val) single nucleotide variant Uncertain significance rs121964871 GRCh37 Chromosome 16, 68857496: 68857496
16 CDH1 NM_004360.4(CDH1): c.2131C> G (p.Leu711Val) single nucleotide variant Uncertain significance rs121964871 GRCh38 Chromosome 16, 68823593: 68823593
17 CDH1 NM_004360.5(CDH1): c.1849G> A (p.Ala617Thr) single nucleotide variant Benign rs33935154 GRCh37 Chromosome 16, 68856041: 68856041
18 CDH1 NM_004360.5(CDH1): c.1849G> A (p.Ala617Thr) single nucleotide variant Benign rs33935154 GRCh38 Chromosome 16, 68822138: 68822138
19 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
20 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh38 Chromosome 12, 25245351: 25245351
21 KRAS NM_004985.4(KRAS): c.40G> A (p.Val14Ile) single nucleotide variant Pathogenic rs104894365 GRCh37 Chromosome 12, 25398279: 25398279
22 KRAS NM_004985.4(KRAS): c.40G> A (p.Val14Ile) single nucleotide variant Pathogenic rs104894365 GRCh38 Chromosome 12, 25245345: 25245345
23 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
24 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic rs79184941 GRCh38 Chromosome 10, 121520163: 121520163
25 FGFR2 NM_000141.4(FGFR2): c.1124A> G (p.Tyr375Cys) single nucleotide variant Pathogenic rs121913478 GRCh37 Chromosome 10, 123274794: 123274794
26 FGFR2 NM_000141.4(FGFR2): c.1124A> G (p.Tyr375Cys) single nucleotide variant Pathogenic rs121913478 GRCh38 Chromosome 10, 121515280: 121515280
27 FGFR2 NM_000141.4(FGFR2): c.1115C> G (p.Ser372Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913477 GRCh37 Chromosome 10, 123274803: 123274803
28 FGFR2 NM_000141.4(FGFR2): c.1115C> G (p.Ser372Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913477 GRCh38 Chromosome 10, 121515289: 121515289
29 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
30 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh38 Chromosome 3, 41224610: 41224610
31 MLH1 NM_000249.3(MLH1): c.1963A> G (p.Ile655Val) single nucleotide variant Likely benign rs55907433 GRCh37 Chromosome 3, 37090074: 37090074
32 MLH1 NM_000249.3(MLH1): c.1963A> G (p.Ile655Val) single nucleotide variant Likely benign rs55907433 GRCh38 Chromosome 3, 37048583: 37048583
33 PTEN NM_000314.7(PTEN): c.235G> A (p.Ala79Thr) single nucleotide variant Likely benign rs202004587 GRCh37 Chromosome 10, 89690828: 89690828
34 PTEN NM_000314.7(PTEN): c.235G> A (p.Ala79Thr) single nucleotide variant Likely benign rs202004587 GRCh38 Chromosome 10, 87931071: 87931071
35 MSH6 NM_000179.2(MSH6): c.2731C> T (p.Arg911Ter) single nucleotide variant Pathogenic rs63751017 GRCh37 Chromosome 2, 48027853: 48027853
36 MSH6 NM_000179.2(MSH6): c.2731C> T (p.Arg911Ter) single nucleotide variant Pathogenic rs63751017 GRCh38 Chromosome 2, 47800714: 47800714
37 PTEN NM_000314.6(PTEN): c.882T> G (p.Ser294Arg) single nucleotide variant Uncertain significance rs143335584 GRCh37 Chromosome 10, 89720731: 89720731
38 PTEN NM_000314.6(PTEN): c.882T> G (p.Ser294Arg) single nucleotide variant Uncertain significance rs143335584 GRCh38 Chromosome 10, 87960974: 87960974
39 PTEN NM_000314.6(PTEN): c.892C> G (p.Gln298Glu) single nucleotide variant Uncertain significance rs371387815 GRCh37 Chromosome 10, 89720741: 89720741
40 PTEN NM_000314.6(PTEN): c.892C> G (p.Gln298Glu) single nucleotide variant Uncertain significance rs371387815 GRCh38 Chromosome 10, 87960984: 87960984
41 ERBB2 NM_001005862.2(ERBB2): c.2416C> T (p.Leu806=) single nucleotide variant not provided rs104886008 GRCh37 Chromosome 17, 37881314: 37881314
42 ERBB2 NM_001005862.2(ERBB2): c.2416C> T (p.Leu806=) single nucleotide variant not provided rs104886008 GRCh38 Chromosome 17, 39725061: 39725061
43 EGFR NM_005228.4(EGFR): c.2544G> A (p.Pro848=) single nucleotide variant not provided rs104886012 GRCh37 Chromosome 7, 55259486: 55259486
44 EGFR NM_005228.4(EGFR): c.2544G> A (p.Pro848=) single nucleotide variant not provided rs104886012 GRCh38 Chromosome 7, 55191793: 55191793
45 EGFR NM_005228.4(EGFR): c.2625+8G> A single nucleotide variant not provided rs104886014 GRCh37 Chromosome 7, 55259575: 55259575
46 EGFR NM_005228.4(EGFR): c.2625+8G> A single nucleotide variant not provided rs104886014 GRCh38 Chromosome 7, 55191882: 55191882
47 BRAF NM_004333.4(BRAF): c.1807C> T (p.Arg603Ter) single nucleotide variant not provided rs104886015 GRCh37 Chromosome 7, 140453128: 140453128
48 BRAF NM_004333.4(BRAF): c.1807C> T (p.Arg603Ter) single nucleotide variant not provided rs104886015 GRCh38 Chromosome 7, 140753328: 140753328
49 PIK3CA NM_006218.3(PIK3CA): c.1540-56C> T single nucleotide variant not provided rs104886002 GRCh37 Chromosome 3, 178935942: 178935942
50 PIK3CA NM_006218.3(PIK3CA): c.1540-56C> T single nucleotide variant not provided rs104886002 GRCh38 Chromosome 3, 179218154: 179218154

Cosmic variations for Endometrial Cancer:

9 (show top 50) (show all 4215)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6935601 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.1124G>T p.S375I 23:15822917-15822917 0
2 COSM6982868 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.854C>A p.S285Y 23:15820233-15820233 0
3 COSM6935600 ZRSR2 endometrium,NS,carcinoma,endometrioid carcinoma c.514T>A p.C172S 23:15809275-15809275 0
4 COSM6845183 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2143C>T p.R715* 16:72958003-72958003 0
5 COSM6845177 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7490C>T p.S2497L 16:72795192-72795192 0
6 COSM6978508 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9856G>A p.A3286T 16:72788420-72788420 0
7 COSM6845125 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2770T>G p.S924A 16:72950915-72950915 0
8 COSM6845174 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4129C>A p.L1377I 16:72798553-72798553 0
9 COSM6845142 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3504G>T p.E1168D 16:72829804-72829804 0
10 COSM6845190 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9555A>C p.Q3185H 16:72788721-72788721 0
11 COSM6845164 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7666G>C p.A2556P 16:72795016-72795016 0
12 COSM6845182 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3628C>T p.R1210* 16:72811940-72811940 0
13 COSM6845133 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2740G>A p.D914N 16:72950945-72950945 0
14 COSM6845156 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2875G>A p.D959N 16:72950810-72950810 0
15 COSM6845152 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1109G>A p.G370D 16:72959037-72959037 0
16 COSM6845162 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6473G>A p.R2158Q 16:72796209-72796209 0
17 COSM973493 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9001G>T p.E3001* 16:72793681-72793681 0
18 COSM6826430 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8002C>T p.R2668* 16:72794680-72794680 0
19 COSM6845155 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.2725G>A p.G909S 16:72950960-72950960 0
20 COSM1233352 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6446G>A p.R2149H 16:72796236-72796236 0
21 COSM6826396 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.568G>A p.V190M 16:72959578-72959578 0
22 COSM6845159 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3829G>A p.V1277M 16:72811612-72811612 0
23 COSM5563443 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6820C>T p.Q2274* 16:72795862-72795862 0
24 COSM6845186 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9266A>C p.E3089A 16:72793416-72793416 0
25 COSM6984593 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6046G>A p.E2016K 16:72796636-72796636 0
26 COSM973492 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.9006G>T p.K3002N 16:72793676-72793676 0
27 COSM6984595 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5623G>A p.E1875K 16:72797059-72797059 0
28 COSM6845173 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3863C>T p.T1288M 16:72811578-72811578 0
29 COSM6845141 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1969G>A p.G657S 16:72958177-72958177 0
30 COSM6982810 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4103A>G p.N1368S 16:72798579-72798579 0
31 COSM6845171 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3115C>T p.H1039Y 16:72950570-72950570 0
32 COSM973535 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4316G>A p.R1439Q 16:72798366-72798366 0
33 COSM1640552 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8849G>A p.R2950H 16:72793833-72793833 0
34 COSM6982809 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4406C>T p.A1469V 16:72798276-72798276 0
35 COSM6984596 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1378G>A p.E460K 16:72958768-72958768 0
36 COSM6845169 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5125G>T p.E1709* 16:72797557-72797557 0
37 COSM6845189 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8228A>G p.Y2743C 16:72794454-72794454 0
38 COSM3276999 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.359G>A p.G120E 16:72959787-72959787 0
39 COSM3276890 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.3397G>A p.E1133K 16:72889782-72889782 0
40 COSM1379731 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.884G>A p.R295H 16:72959262-72959262 0
41 COSM6845185 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5635A>T p.K1879* 16:72797047-72797047 0
42 COSM6845129 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.7559T>C p.L2520P 16:72795123-72795123 0
43 COSM6845179 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8576C>T p.T2859M 16:72794106-72794106 0
44 COSM973560 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.1115G>A p.R372Q 16:72959031-72959031 0
45 COSM6845178 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8197C>A p.R2733S 16:72794485-72794485 0
46 COSM6845161 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5754G>T p.K1918N 16:72796928-72796928 0
47 COSM6845188 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.6058A>G p.K2020E 16:72796624-72796624 0
48 COSM6984594 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.5941G>A p.E1981K 16:72796741-72796741 0
49 COSM6845165 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.8078G>A p.R2693Q 16:72794604-72794604 0
50 COSM6845127 ZFHX3 endometrium,NS,carcinoma,endometrioid carcinoma c.4274T>C p.I1425T 16:72798408-72798408 0

Copy number variations for Endometrial Cancer from CNVD:

7 (show top 50) (show all 66)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14799 1 110230418 110236367 Duplication GSTM1 Endometrial cancer
2 16430 1 124300000 247249719 Gain Endometrial cancer
3 16431 1 124300000 247249719 Gain Endometrial cancer
4 16443 1 124300000 247249719 Gain or loss Endometrial cancer
5 30005 1 23900000 28000000 Copy number STMN1 Endometrial cancer
6 38170 10 1 40300000 Gain Endometrial cancer
7 38173 10 1 40300000 Gain or loss Endometrial cancer
8 42809 10 40300000 135374737 Gain Endometrial cancer
9 42810 10 40300000 135374737 Gain or loss Endometrial cancer
10 47133 10 89613174 89718512 Copy number PTEN Endometrial cancer
11 47161 10 89623194 89728531 Loss PTEN Endometrial cancer
12 48495 11 1 52900000 Gain or loss Endometrial cancer
13 55432 11 52900000 134452384 Gain or loss Endometrial cancer
14 61536 12 1 35400000 Gain or loss Endometrial cancer
15 66123 12 25358179 25403863 Amplification KRAS Endometrial cancer
16 75150 13 16000000 114142980 Gain or loss Endometrial cancer
17 82814 14 15600000 106368585 Gain or loss Endometrial cancer
18 89241 15 17000000 100338915 Gain or loss Endometrial cancer
19 97274 16 1 38200000 Gain Endometrial cancer
20 97276 16 1 38200000 Gain or loss Endometrial cancer
21 101463 16 38200000 88827254 Gain or loss Endometrial cancer
22 106793 17 1 22200000 Gain or loss Endometrial cancer
23 108760 17 22200000 78774742 Gain or loss Endometrial cancer
24 119170 18 1 16100000 Gain or loss Endometrial cancer
25 119734 18 16100000 76117153 Gain or loss Endometrial cancer
26 124098 19 1 28500000 Gain or loss Endometrial cancer
27 127175 19 28500000 63811651 Gain or loss Endometrial cancer
28 134355 2 1 93300000 Gain or loss Endometrial cancer
29 146256 2 47483766 47760012 Rearrangement MSH2 Endometrial cancer
30 149784 2 93300000 242951149 Gain or loss Endometrial cancer
31 150416 20 1 27100000 Gain or loss Endometrial cancer
32 151944 20 27100000 62435964 Gain Endometrial cancer
33 151953 20 27100000 62435964 Gain or loss Endometrial cancer
34 157114 21 12300000 46944323 Gain or loss Endometrial cancer
35 160291 22 11800000 49691432 Gain or loss Endometrial cancer
36 163141 22 24376139 24384284 Duplication GSTT1 Endometrial cancer
37 166155 3 1 91700000 Gain or loss Endometrial cancer
38 172027 3 175700000 179000000 Amplification PIK3CA Endometrial cancer
39 175016 3 37009982 37067341 Rearrangement MLH1 Endometrial cancer
40 179466 3 91700000 199501827 Gain or loss Endometrial cancer
41 179984 4 1 50700000 Gain or loss Endometrial cancer
42 187532 4 50700000 191273063 Gain or loss Endometrial cancer
43 200012 5 47700000 180857866 Gain or loss Endometrial cancer
44 203699 6 1 60500000 Gain or loss Endometrial cancer
45 214470 6 60500000 170899992 Gain or loss Endometrial cancer
46 217117 7 1 59100000 Gain or loss Endometrial cancer
47 226563 7 59100000 158821424 Gain or loss Endometrial cancer
48 230833 8 1 45200000 Gain or loss Endometrial cancer
49 240068 8 45200000 146274826 Gain Endometrial cancer
50 240080 8 45200000 146274826 Gain or loss Endometrial cancer

Expression for Endometrial Cancer

Search GEO for disease gene expression data for Endometrial Cancer.

Pathways for Endometrial Cancer

Pathways related to Endometrial Cancer according to KEGG:

38
# Name Kegg Source Accession
1 Endometrial cancer hsa05213

Pathways related to Endometrial Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 CDH1 CTNNB1 FGFR2 KRAS MSH3 MSH6
2
Show member pathways
12.47 CDH1 CTNNB1 FGFR2 KRAS PTEN
3
Show member pathways
12.43 CDH1 FGFR2 KRAS MSH6 PTEN
4 11.94 CDH1 CTNNB1 KRAS MSH3 MSH6
5 11.89 CDH1 CTNNB1 FGFR2 KRAS MSH3 MSH6
6 11.76 CTNNB1 KRAS PTEN
7 11.73 CTNNB1 KRAS PTEN
8 11.68 CDH1 CTNNB1 FGFR2
9
Show member pathways
11.64 MLH3 MSH3 MSH6
10 11.54 CDH1 CTNNB1 KRAS MSH6 PTEN
11 11.36 FGFR2 KRAS PTEN
12 10.57 CDH1 CTNNB1
13 10.41 HOTAIR LINC-ROR UCA1

GO Terms for Endometrial Cancer

Cellular components related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.96 CDH1 CTNNB1
2 mismatch repair complex GO:0032300 8.8 MLH3 MSH3 MSH6

Biological processes related to Endometrial Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of endothelial cell differentiation GO:0045603 9.55 CTNNB1 MIR200C
2 epithelial tube branching involved in lung morphogenesis GO:0060441 9.54 CTNNB1 KRAS
3 negative regulation of DNA recombination GO:0045910 9.52 MSH3 MSH6
4 regulation of osteoblast differentiation GO:0045667 9.51 CTNNB1 FGFR2
5 regulation of synaptic transmission, GABAergic GO:0032228 9.49 KRAS PTEN
6 morphogenesis of embryonic epithelium GO:0016331 9.48 CTNNB1 FGFR2
7 entry of bacterium into host cell GO:0035635 9.46 CDH1 CTNNB1
8 lung-associated mesenchyme development GO:0060484 9.43 CTNNB1 FGFR2
9 positive regulation of helicase activity GO:0051096 9.4 MSH3 MSH6
10 replication fork arrest GO:0043111 9.37 MSH3 MSH6
11 cellular response to indole-3-methanol GO:0071681 9.32 CDH1 CTNNB1
12 maintenance of DNA repeat elements GO:0043570 9.26 MSH3 MSH6
13 meiotic mismatch repair GO:0000710 9.16 MSH3 MSH6
14 mesenchymal cell proliferation involved in lung development GO:0060916 8.96 CTNNB1 FGFR2
15 mismatch repair GO:0006298 8.92 MLH3 MSH3 MSH6 MUTYH

Molecular functions related to Endometrial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MutLalpha complex binding GO:0032405 9.37 MSH6 MUTYH
2 guanine/thymine mispair binding GO:0032137 9.32 MSH3 MSH6
3 single thymine insertion binding GO:0032143 9.26 MSH3 MSH6
4 single guanine insertion binding GO:0032142 9.16 MSH3 MSH6
5 mismatched DNA binding GO:0030983 9.13 MLH3 MSH3 MSH6
6 centromeric DNA binding GO:0019237 9.1 MLH3
7 oxidized purine DNA binding GO:0032357 8.8 MSH3 MSH6 MUTYH

Sources for Endometrial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38